All In Biotech

Drug Trial Radar · NCT05987423

Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease

A Phase III, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Moderate-to-Severe Thyroid Eye Disease

Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

131

Actual

Start

Oct 26, 2023

Primary completion

Jul 8, 2025

Study completion Jun 25, 2026

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Aug 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous (SC) satralizumab, a recombinant, humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody, in participants with thyroid eye disease (TED).

Conditions

  • Thyroid Eye Disease
  • TED

Interventions

  • SatralizumabDrug

    Satralizumab will be administered by SC injection.

  • PlaceboDrug

    Placebo will be administered by SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants in the Active TED Population Who Achieved ≥ 2 Millimeters (mm) Reduction in Proptosis From Baseline at Week 24 in the Study EyeTime frame: At Week 24

Locations

46 sites in 10 countries. Site status is shown where the registry gives one.

  • Thrive Health Research LLC

    Beverly Hills, California

  • UCSD Shiley Eye Center

    La Jolla, California

  • Grene Vision Group, LLC

    Wichita, Kansas

  • Johns Hopkins University

    Baltimore, Maryland

  • University of Michigan, Kellogg Eye Center

    Ann Arbor, Michigan

  • Great Lakes Eye Care

    Saint Joseph, Michigan

  • 'Northwell Health Physician Partners Ophthalmology

    Great Neck, New York

  • EyeHealth Northwest

    Portland, Oregon

  • Austin Retina Associates

    Austin, Texas

  • Eyelid Center of Utah

    Salt Lake City, Utah

  • WVU Eye Institute

    Morgantown, West Virginia

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    Buenos Aires, Argentina

  • Centro Oftalmologico Dr. Charles S.A.

    Capital Federal, Argentina

  • Oftalmos

    Capital Federal, Argentina

  • Buenos Aires Mácula

    Ciudad Autonoma Buenos Aires, Argentina

  • Centrovision Mendoza

    Mendoza, Argentina

  • Grupo Laser Vision

    Rosario, Argentina

  • Sydney Eye Hospital

    Sydney, New South Wales, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Centre For Eye Research Australia

    East Melbourne, Victoria, Australia

  • Medizinische Universitat Wien

    Vienna, Austria

  • Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum

    Berlin, Germany

  • Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Augenheilkunde

    Dresden, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Universitätsklinikum Freiburg, Klinik für Augenheilkunde

    Freiburg im Breisgau, Germany

  • Universitatsklinikum Munster

    Münster, Germany

  • Universitäts-Augenklinik Tübingen

    Tübingen, Germany

  • Hong Kong Eye Hospital

    Mong Kok, Hong Kong

  • Budapest Retina Associates Kft.

    Budapest, Hungary

  • A.O. U. Federico II

    Naples, Campania, Italy

  • Fondazione Policlinico Universitario A Gemelli

    Rome, Lazio, Italy

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy

  • Ospedale Di Circolo E Fondazione Macchi

    Varese, Lombardy, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, Tuscany, Italy

  • Aichi Medical University Hospital

    Aichi, Japan

  • Kyushu University Hospital

    Fukuoka, Japan

  • Social Medical Corporation Tenjinkai Shinkoga Hospital

    Fukuoka, Japan

  • Hokkaido University Hospital

    Hokkaido, Japan

  • Kobe Kaisei Hospital Medical foundation

    Hyōgo, Japan

  • Hospital of the University of Occupational and Environmental Health,Japan

    Kitakyushu-shi, Japan

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.